Stock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses

Stock Track

2025/09/08

Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.

Key highlights from Burning Rock's Q2 2025 earnings report include: - Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million) - Gross profit rose 13.3% to RMB108.1 million (US$15.1 million) - Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million) - Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024

The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1117246220"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117246220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117246220?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117246220","market":"hk","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses","media":"Stock Track","content":"<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.</p>\n\n<p>Key highlights from Burning Rock's Q2 2025 earnings report include:\n- Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million)\n- Gross profit rose 13.3% to RMB108.1 million (US$15.1 million)\n- Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million)\n- Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024</p>\n\n<p>The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 7.83% on Strong Q2 Results and Narrowed Losses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-09-08 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.</p>\n\n<p>Key highlights from Burning Rock's Q2 2025 earnings report include:\n- Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million)\n- Gross profit rose 13.3% to RMB108.1 million (US$15.1 million)\n- Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million)\n- Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024</p>\n\n<p>The company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石醫學","start_time":0,"source_url":"","article_id":"1117246220","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117246220","pubTimestamp":1757338342,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股赛道|燃石生物大涨7.83%Q2业绩强劲亏损收窄","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged 7.83% in pre-market trading on Monday after the precision oncology company reported better-than-expected second quarter 2025 financial results. The significant improvement in revenue growth and cost control measures led to a substantial reduction in losses, exciting investors.\nKey highlights from Burning Rock's Q2 2025 earnings report include:\n- Total revenues increased 9.6% year-over-year to RMB148.5 million (US$20.7 million)\n- Gross profit rose 13.3% to RMB108.1 million (US$15.1 million)\n- Operating expenses decreased 42.1% to RMB119.6 million (US$16.7 million)\n- Net loss narrowed to RMB9.7 million (US$1.4 million), compared to RMB108.0 million in Q2 2024\nThe company's pharma research and development services segment showed particularly strong growth, with revenue increasing 68.1% year-over-year. This growth, combined with effective cost management across all business segments, contributed to the improved financial performance. Investors appear to be responding positively to Burning Rock's progress in reducing losses while maintaining revenue growth, driving the stock's significant uptick in the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}